Biotech Analyst Joins Board of Directors of Marshall Edwards, Inc.
19. März 2009 13:07 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - March 19, 2009) - Marshall Edwards, Inc.
(NASDAQ: MSHL) is pleased to announce the appointment of Leah Cann to the
Board of Directors of the...
Marshall Edwards' Phenoxodiol and Novogen's NV-128 Display Divergent Mechanisms of Action but Potent Synergistic Anti-Cancer Activity When Used in Combination
30. Oktober 2008 19:19 ET
|
Novogen, Limited
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - October 30, 2008) - Pre-clinical studies
presented at the 9th International Conference on Membrane Redox Systems in
Wellington New Zealand this...
Marshall Edwards, Inc.'s Investigational Drug Triphendiol (NV-196) Demonstrates Potent Activity Against Biliary Cancers
13. April 2008 16:00 ET
|
Marshall Edwards, Inc.
SAN DIEGO, CA--(Marketwire - April 13, 2008) - Pre-clinical studies presented here today at
the annual meeting of the American Association for Cancer Research
demonstrate that Marshall Edwards,...
Phenoxodiol Trials Highlighted at Ovarian Cancer Action International Conference
10. März 2008 08:00 ET
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and LONDON and NEW CANAAN, CT--(Marketwire - March 10, 2008) - The role of
the investigational drug phenoxodiol in restoration of chemosensitivity in
ovarian cancer patients...
Additional Orphan Drug Status Granted for Melanoma for Marshall Edwards' Investigational Anti-Cancer Drug Triphendiol (NV-196)
19. Februar 2008 07:31 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - February 19, 2008) - Marshall Edwards, Inc., (NASDAQ: MSHL)
announced today that triphendiol (previously known as NV-196) has been
granted Orphan Drug status by the U.S....
Novogen NV-128 Induces Novel Mode of Cell Death in Cancer Cells
24. Oktober 2007 08:07 ET
|
Novogen
SAN FRANCISCO, CA--(Marketwire - October 24, 2007) - Laboratory studies presented late
yesterday at the annual AACR/EORTC/NCI Molecular Targets and Cancer
Therapeutics conference demonstrate that...